Companion Animal Arthritis Market Analysis

Companion Animal Arthritis Market Analysis

To get key market trends

  Download Free Sample

Based on treatment type, the market is segmented into medication, food supplement, surgery and other treatment types. The medication segment is further bifurcate into NSAIDs, monoclonal antibodies, and other medications. The medication segment is estimated to account for USD 1.5 billion in 2023.
 

• Veterinarians prescribe pharmaceutical drugs, including NSAIDs, corticosteroids, and disease-modifying osteoarthritis drugs (DMOADs), to relieve arthritis symptoms in companion animals, focusing on pain relief and reducing inflammation. 
   
• Advancements in veterinary medicine, such as better diagnostics, stronger medications, and comprehensive treatment protocols, improve the effectiveness and accessibility of arthritis treatments.
   
• While medications currently dominate the market due to their effectiveness in managing symptoms, alternative therapies and regenerative medicines are becoming popular for promoting joint health and mobility in aging or arthritic pets.
   
• The introduction of biologic therapies, such as monoclonal antibodies and stem cell treatments, has expanded treatment options for arthritis in companion animals, contributing to market growth.
   

Based on disease type the companion animal arthritis market is segmented into osteoarthritis, rheumatoid arthritis, and other arthritis types. The osteoarthritis segment dominated the market with the market share of 64.3% in 2023.
 

• Osteoarthritis, a common form of arthritis in pets, affects up to 20% of older dogs and cats, causing joint cartilage degeneration and bone changes.
   
• The growing consumer preference for natural and holistic treatments, including nutraceuticals like glucosamine, chondroitin, and omega-3 fatty acids, is expected to increase the demand for products managing osteoarthritis in dogs, thereby driving market growth.
   

Based on animal type the companion animal arthritis market is segmented into dogs, cats, and other animals. The dogs’ segment is expected to reach USD 4.5 billion by 2032.
 

• Older dogs and certain breeds, like Labrador Retrievers and German Shepherds, are particularly susceptible to arthritis.
   
• As pet adoption rates climb, so do expenditures on pet healthcare supplies and services. Pet owners are increasingly investing in canine arthritis treatments, aiming to enhance their dogs' quality of life.
   
• The market for animal arthritis therapies is witnessing swift expansion, with emerging trends hinting at new solutions to further elevate the quality of life for dogs, fueling the market's growth.
   

Based on end-use, the companion animal arthritis market is segmented into veterinary hospitals, veterinary clinics, veterinary rehabilitation centers, and other end-users. The veterinary hospitals segment is expected to exhibit 7.3% CAGR between 2024 – 2032.
 

• Veterinary hospitals provide a wide range of services, including surgical procedures, physical therapy, and continuous monitoring of arthritis progression. Pet owners depend on veterinarians for expert guidance on managing arthritis, including treatment options and dosages.
   
• As pet ownership rises due to companionship, health benefits, and lifestyle changes, the demand for veterinary services grows. This includes routine checkups, vaccinations, and treatments for conditions like arthritis. Increased visits to veterinary hospitals boost the demand for medications and therapies, driving market growth.

In 2023, North America commanded a dominant 45.6% share of the global companion animal arthritis market, with projections indicating robust growth throughout the analysis period.
 

• Factors such as rising pet ownership, heightened awareness of animal health, and advancements in veterinary care are driving the significant expansion of the market in North America.
   
• As the pet care industry evolves, stakeholders in the North American market stand to gain, especially those who innovate and cater to the market's distinct needs.
   

These dynamics underscore North America's leading position in the companion animal arthritis market.
 

Forecasts suggest the U.S. market will grow at a CAGR of 7.1% from 2024 – 2032.
 

• With a robust network of hospitals and veterinary clinics, pet owners in both urban and rural U.S. locales enjoy easily accessible healthcare services.
   
• As pet ownership knowledge grows, so do the associated health costs, especially for chronic treatments like arthritis.
   

Germany is poised to lead in growth within the European companion animal arthritis market.
 

• Boasting one of Europe's highest pet ownership rates, many German households own dogs and cats. This demographic trend lays a solid foundation for the expansion of the veterinary care industry, especially for ailments like arthritis.
   
• Through technological advancements in diagnostics, therapeutics, and surgical techniques, Germany is elevating veterinary medicine, broadening and enhancing treatment options for conditions like arthritis in companion animals.
   

In the Asia-Pacific region, the companion animal arthritis market is projected to grow at a notable CAGR of 7.6% during the forecast period.
 

• Countries in the Asia-Pacific are adopting cutting-edge technologies in veterinary medicine, from medications and therapeutic approaches for arthritis to advanced diagnostic tools, ensuring better access to specialized care.
   
• Economic growth and rising disposable incomes across many Asia-Pacific nations have spurred increased spending on pet healthcare. This trend sees pet owners more inclined to invest in advanced treatments and therapies, fueling market growth.